Loading insider details...
Beta
Latest Form 4 (Sep 4, 2026): Sale of 10,824 DNLI shares, $247.3K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | Denali Therapeutics Inc. (DNLI) | Sale | 10,824 | $247.3K |
| Jun 23, 2026 | Schrodinger, Inc. (SDGR) | Grant/Award | 8,141 | n/a |
| Jun 5, 2026 | Denali Therapeutics Inc. (DNLI) | Grant/Award | 6,408 | n/a |
| May 5, 2026 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/Award | 472 | n/a |
| Jun 20, 2025 | Schrodinger, Inc. (SDGR) | Grant/Award | 5,997 | n/a |
| Jun 5, 2025 | Denali Therapeutics Inc. (DNLI) | Grant/Award | 6,037 | n/a |
| May 5, 2025 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/Award | 398 | n/a |
| Jun 20, 2024 | Schrodinger, Inc. (SDGR) | Grant/Award | 5,000 | n/a |
| Jun 4, 2024 | Denali Therapeutics Inc. (DNLI) | Grant/Award | 5,967 | n/a |
| May 3, 2024 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/Award | 501 | n/a |